TY - JOUR
T1 - Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM)
T2 - Design and implementation of a prospective/retrospective rolling cohort study
AU - MCAM Study Group
AU - Unger, Elizabeth R.
AU - Lin, Jin Mann S.
AU - Tian, Hao
AU - Natelson, Benjamin H.
AU - Lange, Gudrun
AU - Vu, Diana
AU - Blate, Michelle
AU - Klimas, Nancy G.
AU - Balbin, Elizabeth G.
AU - Bateman, Lucinda
AU - Allen, Ali
AU - Lapp, Charles W.
AU - Springs, Wendy
AU - Kogelnik, Andreas M.
AU - Phan, Catrina C.
AU - Danver, Joan
AU - Podell, Richard N.
AU - Fitzpatrick, Trisha
AU - Peterson, Daniel L.
AU - Gottschalk, C. Gunnar
AU - Rajeevan, Mangalathu S.
AU - Bae, Jaeyon
AU - Blocker, Felicia
AU - Boneva, Roumiana
AU - Bonner, Kathleen
AU - Brimmer, Dana
AU - Burns, Jordan
AU - Campbell, Charlotte
AU - Chuang, Judith
AU - Cornelius, Monica
AU - Dimulescu, Irina
AU - Emanuele, Vince
AU - Groth, Alyx
AU - Gurbaxani, Brian
AU - Hagaman, Ashley
AU - Hasenstab, Kyle
AU - Haynes, Colleen
AU - Helton, Britany
AU - Ho, Joyce
AU - Jones, James F.
AU - Khin, Maung Maung
AU - Lee, Daisy
AU - McLoed, Timothy
AU - Oakley, Lisa
AU - Pao, Alex
AU - Philyaw, Meredith
AU - Piervil, Esther
AU - Querec, Troy
AU - Rai, Ashish
AU - Richards, Jendai
N1 - Publisher Copyright:
© 2017 The Author.
PY - 2017/4/15
Y1 - 2017/4/15
N2 - In the Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we relied on expert clinician diagnoses to enroll patients from 7 specialty clinics in the United States in order to perform a systematic collection of data on measures of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Healthy persons and those with other illnesses that share some features with ME/CFS were enrolled in comparison groups. The major objectives were to: 1) use standardized questionnaires to measure illness domains of ME/CFS and to evaluate patient heterogeneity overall and between clinics; 2) describe the course of illness, identify the measures that best correlate with meaningful clinical differences, and assess the performances of questionnaires as patient/person-reported outcome measures; 3) describe prescribed medications, orders for laboratory and other tests, and management tools used by expert clinicians to care for persons with ME/CFS; 4) collect biospecimens for future hypothesis testing and for evaluation of morning cortisol profiles; and 5) identify measures that best distinguish persons with ME/CFS from those in the comparison groups and detect subgroups of persons with ME/CFS who may have different underlying causes. Enrollment began in 2012 and is planned to continue in multiple stages through 2017. We present the MCAM methods in detail, along with an initial description of the 471 patients with ME/CFS who were enrolled in stage 1.
AB - In the Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we relied on expert clinician diagnoses to enroll patients from 7 specialty clinics in the United States in order to perform a systematic collection of data on measures of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Healthy persons and those with other illnesses that share some features with ME/CFS were enrolled in comparison groups. The major objectives were to: 1) use standardized questionnaires to measure illness domains of ME/CFS and to evaluate patient heterogeneity overall and between clinics; 2) describe the course of illness, identify the measures that best correlate with meaningful clinical differences, and assess the performances of questionnaires as patient/person-reported outcome measures; 3) describe prescribed medications, orders for laboratory and other tests, and management tools used by expert clinicians to care for persons with ME/CFS; 4) collect biospecimens for future hypothesis testing and for evaluation of morning cortisol profiles; and 5) identify measures that best distinguish persons with ME/CFS from those in the comparison groups and detect subgroups of persons with ME/CFS who may have different underlying causes. Enrollment began in 2012 and is planned to continue in multiple stages through 2017. We present the MCAM methods in detail, along with an initial description of the 471 patients with ME/CFS who were enrolled in stage 1.
KW - Chronic fatigue syndrome
KW - Myalgic encephalomyelitis
KW - Patient-reported outcome measures
KW - Study methods
UR - https://www.scopus.com/pages/publications/85019703995
UR - https://www.scopus.com/pages/publications/85019703995#tab=citedBy
U2 - 10.1093/aje/kwx029
DO - 10.1093/aje/kwx029
M3 - Article
C2 - 28338983
AN - SCOPUS:85019703995
SN - 0002-9262
VL - 185
SP - 617
EP - 626
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
IS - 8
ER -